Aspira Women’s Health Inc. to Report Second Quarter 2021 Financial Results on August 12
About Aspira Womens Health Inc.
- About Aspira Womens Health Inc.
Aspira Womens Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. - Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.
- OVA1 plus includes our FDA-cleared products, OVA1 and OVERA, to detect risk of ovarian malignancy in women with adnexal masses.
- With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research.